Compugen (NASDAQ:CGEN) Announces Quarterly Earnings Results

Compugen (NASDAQ:CGEN) issued its earnings results on Monday. The biotechnology company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.02, FiscalAI reports. The firm had revenue of $3.82 million during the quarter, compared to the consensus estimate of $1.28 million. Compugen had a net margin of 47.56% and a return on equity of 42.57%.

Compugen Stock Performance

Shares of CGEN stock opened at $1.96 on Monday. The firm’s fifty day moving average price is $2.25 and its two-hundred day moving average price is $2.29. Compugen has a 1 year low of $1.43 and a 1 year high of $3.23. The firm has a market capitalization of $185.32 million, a P/E ratio of 5.16 and a beta of 2.85.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Weiss Ratings reissued a “hold (c-)” rating on shares of Compugen in a report on Tuesday, November 3rd. HC Wainwright reaffirmed a “buy” rating and set a $4.00 price objective on shares of Compugen in a research note on Monday, October 12th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $5.00.

About Compugen

Compugen Ltd. (NASDAQ: CGEN) is an Israeli clinical-stage biotechnology company focused on discovering and developing novel therapeutic and drug targets for cancer and other diseases. The company uses computational biology and artificial intelligence-based approaches to identify previously unrecognized biological mechanisms and translate them into potential medicines.

Compugen’s research has primarily centered on immuno-oncology, with an emphasis on regulating immune responses within the tumor microenvironment.